Zhaoyan New Pharmaceutical (603127.SH) issued an announcement. The company received China's securities regulation on February 8, 2024...
Zhitong Finance App News, Zhaoyan New Pharmaceutical (603127.SH) issued an announcement. The company received the “Decision on Measures Issuing Warning Letters against Feng Yuxia and Zhou Zhiwen” issued by the Beijing Regulatory Bureau of the China Securities Regulatory Commission on February 8, 2024.
According to the investigation, from November 5, 2020 to February 26, 2021, the proportion of shares held by Feng Yuxia and Zhou Zhiwen decreased by a cumulative total of 8.16% due to passive dilution and active reduction of H shares. Feng Yuxia and Zhou Zhiwen, as actual controllers and co-actors of Beijing Zhaoyan New Pharmaceutical Research Center Co., Ltd., did not stop trading the company's shares and promptly prepared and disclosed equity change reports when the shareholding ratio was reduced to 5%. They were not disclosed until May 27, 2022, when the cumulative change in shares accounted for 9.16% of the company's total share capital. The above acts violate the provisions of Article 63 of the Securities Law and Article 13 of the “Administrative Measures on Takeovers of Listed Companies”. According to the provisions of Article 75 of the “Administrative Measures on Acquisitions of Listed Companies”, the Beijing Securities Regulatory Bureau takes administrative supervision measures to issue a warning letter against them.